(Q28323157)

6 July 2017

Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis (English)

1 reference

6 July 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A235486

22 January 2023

author name string

R. E. Pounder

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A235486

22 January 2023

E. R. Craven

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A235486

22 January 2023

J. S. Henthorn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A235486

22 January 2023

J. M. Bannatyne

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A235486

22 January 2023

language of work or name

English

0 references

publication date

1 March 1975

1 reference

full work available at URL

6 July 2017

https://europepmc.org/articles/PMC1410952

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A235486

https://europepmc.org/articles/PMC1410952?pdf=render

22 January 2023

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A235486

https://syndication.highwire.org/content/doi/10.1136/gut.16.3.181

22 January 2023

1 reference

https://api.crossref.org/works/10.1136/GUT.16.3.181

22 January 2023

1 reference

6 July 2017

16

1 reference

6 July 2017

181-185

1 reference

6 July 2017

3

1 reference

A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

6 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410952

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410952

Drug-associated blood dyscrasias. Recent additions to the Registry

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410952

Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410952

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410952

Ulcerative colitis and erythrocyte G6PD deficiency. Salicylazosulfapyridine-provoked hemolysis

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410952

Letter: Hemolytic anemia as adverse reaction to salicylazosulfapyridine

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410952

The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410952

Letter: Hyposplenism in ulcerative colitis.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410952

Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410952

THE OCCURRENCE OF HEINZ BODIES DURING AZULFIDINE TREATMENT OF ULCERATIVE COLITIS.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1410952

PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION

27 November 2018

1 reference

12 December 2020

HEMOLYTIC ANEMIA SECONDARY TO SALICYLAZOSULFAPYRIDINE THERAPY

1 reference

12 December 2020

Heinz-body anaemia due to salicylazosulphapyridine

1 reference

12 December 2020

Hyposplenism in ulcerative colitis

1 reference

12 December 2020

Absorption, metabolism, and excretion of salicylazosulfapyridine in man

1 reference

12 December 2020

Impaired folic acid absorption in inflammatory bowel disease: effects of salicylazosulfapyridine (Azulfidine)

https://api.crossref.org/works/10.1136/GUT.16.3.181

13

1 reference

22 January 2023

Identifiers

DOI

10.1136/GUT.16.3.181

1 reference

6 July 2017

1 reference

6 July 2017

1 reference